COMP <GO>
TNGX vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Tango Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TNGX 2
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $22.72 (+0.84%) • MKT CAP: $3.83B
roic
-28.90%
LAST: $273.20 (-0.73%) • MKT CAP: $657.68B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNGX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TNGX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -28.90% | 25.50% | -54.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.68% | 2.97% | -6.65 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 48.30% | 6.00% | +42.30 | TNGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | TNGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.9 | 59.1 | -12.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.08 | -0.21 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 23.0x | +5.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.83B | $657.68B | -$653.85B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TNGX REV | JNJ REV | TNGX GROSS % | JNJ GROSS % | TNGX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.4M | $94.19B | — | 67.9% | -$139.9M | $19.70B |
| FY 2024 | $42.1M | $88.82B | — | 69.1% | -$132.3M | $19.84B |
| FY 2023 | $36.5M | $85.16B | — | — | -$119.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNGX // BETA 0.87
JNJ // BETA 1.08